• Prescribing Information
  • Patient Information
  • Patient Site
  • Medical Information
  • Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

    Click here to learn how we are responding.

    TOVIAZ® (fesoterodine fumarate) Tablets Logo

    TOVIAZ

    TOVIAZ: proven to help control overactive bladder symptoms

    Efficacy & Safety in overactive bladder (OAB)

    Review data

    Landmark Study in Medically Complex Elderly OAB Patients

    Review data

    Patient Resources

    Access resources

    TOVIAZ starters* delivered right to your office

        •   The recommended starting dose of TOVIAZ is 4 mg once daily.1

        •   Increasing to 8 mg once daily is an option based on individual response and tolerability.1​​​​​

        •   Doses greater than 4 mg are not recommended in patients with severe renal insufficiency (CLCR <30 mL/min), or in patients taking a potent CYP3A4 inhibitor, such as ketoconazole, itraconazole, and clarithromycin.​​​​​​​1

     ​​​​​​​*For eligible healthcare providers.

    TOVIAZ for overactive bladder (OAB) patients with symptoms of urge urinary incontinence (UUI)

    Review data


    Reference

    ​​​​​​​    1.     Toviaz [package insert]. New York, NY: Pfizer Inc.; 2017.

    INDICATION

    TOVIAZ® (fesoterodine fumarate) is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

    Contraindications

    TOVIAZ® (fesoterodine fumarate) is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and in patients with known hypersensitivity to the drug or its ingredients or to DETROL® (tolterodine tartrate) tablets or DETROL® LA (tolterodine tartrate extended release capsules).

    Warnings and Precautions

    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine, in some cases after the first dose. Patients should be advised to promptly discontinue fesoterodine therapy and seek immediate medical attention if they experience edema of the tongue, laryngopharynx, or difficult breathing.

    TOVIAZ tablets should be used with caution in patients with clinically significant bladder outlet obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or myasthenia gravis.

    TOVIAZ is associated with anticholinergic central nervous system (CNS) effects including headache, dizziness and somnolence. Advise patients not to drive or operate heavy machinery until they know how TOVIAZ affects them. Consider dose reduction or drug discontinuation if a patient experiences anticholinergic CNS effects.

    The recommended starting dose of TOVIAZ is 4 mg once daily swallowed whole. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily. Doses greater than 4 mg are not recommended in patients with severe renal insufficiency (CLCR <30 mL/min), or in patients taking a potent CYP3A4 inhibitor, such as ketoconazole, itraconazole, and clarithromycin. TOVIAZ is not recommended for use in patients with severe hepatic impairment (Child-Pugh C).

    Adverse Events

    The most frequently reported adverse events (≥4%) for TOVIAZ were: dry mouth (placebo, 7%; TOVIAZ 4 mg, 19%; TOVIAZ 8 mg, 35%) and constipation (placebo, 2%; TOVIAZ 4 mg, 4%; TOVIAZ 8 mg, 6%).


    Please see full Prescribing Information and Patient Information.

    TOVIAZ® (fesoterodine fumarate) is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.